clinical trial · NCT06536465
The Clostridioides Difficile Trial of REC-3964
Recurrent Clostridioides Difficile InfectionREC-3964
brief summary
This is a multi-center, open-label study to investigate the safety, tolerability, pharmacokinetics (PK) and efficacy of REC-3964 (doses of either 250 mg or 500 mg PO every 12 hours) for the reduction of Clostridioides difficile infection (CDI).
started
Oct 14, 2024
primary completion
May 6, 2025
completion
May 6, 2025
last updated
Nov 17, 2025
detailed description
Study was terminated due to sponsor decision. This decision was not related to safety concerns.
official title
A Phase 2 Clinical Study of REC-3964 in Adults for the Reduction of Recurrent Clostridioides Difficile Infection (CDI)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol